Genmab (GE91) Stock Statistics & Valuation Metrics
Total Valuation
Genmab has a market cap or net worth of EUR 31.15B. The enterprise value is EUR 20.72B.
- Market Cap
- EUR 31.15B
- Enterprise Value
- EUR 20.72B
Share Statistics
Genmab has 624,058,530 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 624,058,530
- Owned by Insiders
- ―
- Owned by Institutions
- 2.18%
Financial Efficiency
Genmab’s return on equity (ROE) is 0.17 and return on invested capital (ROIC) is 8.54%.
- Return on Equity (ROE)
- 0.17
- Return on Assets (ROA)
- 0.08
- Return on Invested Capital (ROIC)
- 8.54%
- Return on Capital Employed (ROCE)
- 0.11
- Revenue Per Employee
- 1.19M
- Profits Per Employee
- 309.00K
- Employee Count
- 3,119
- Asset Turnover
- 0.29
- Inventory Turnover
- 17.22
Valuation Ratios
The current PE Ratio of Genmab is 45.64. Genmab’s PEG ratio is -0.53.
- PE Ratio
- 45.64
- PS Ratio
- 3.72
- PB Ratio
- 6.01
- Price to FCF
- 41.29
- Price to Operating Cash Flow
- 40.12
- PEG Ratio
- -0.53
Income Statement
In the last 12 months, Genmab had revenue of 3.72B and earned 963.76M in profits. Earnings per share was 1.55.
- Revenue
- 3.72B
- Gross Profit
- 3.41B
- Operating Income
- 1.25B
- Pretax Income
- 1.20B
- Net Income
- 963.76M
- EBITDA
- 1.34B
- Earnings Per Share (EPS)
- 1.55
Cash Flow
In the last 12 months, operating cash flow was 890.35M and capital expenditures -23.00M, giving a free cash flow of 867.34M billion.
- Operating Cash Flow
- 890.35M
- Free Cash Flow
- 867.34M
- Free Cash Flow per Share
- 1.42
Dividends & Yields
Genmab pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.42%
- Earnings Yield
- 2.20%
Stock Price Statistics
- Beta
- 0.70
- 52-Week Price Change
- 101.61%
- 50-Day Moving Average
- 31.30
- 200-Day Moving Average
- 25.79
- Relative Strength Index (RSI)
- 91.82
- Average Volume (3m)
- 124
Important Dates
Genmab upcoming earnings date is Nov 05, 2026, During Market Hours (Not Confirmed).
- Last Earnings Date
- Aug 06, 2026
- Next Earnings Date
- Nov 05, 2026
- Ex-Dividend Date
- ―
Financial Position
Genmab as a current ratio of 2.02, with Debt / Equity ratio of 93.01%
- Current Ratio
- 2.02
- Quick Ratio
- 2.01
- Debt to Market Cap
- 0.28
- Net Debt to EBITDA
- 2.78
- Interest Coverage Ratio
- 20.49
Taxes
In the past 12 months, Genmab has paid 241.19M in taxes.
- Income Tax
- 241.19M
- Effective Tax Rate
- 0.20
Enterprise Valuation
Genmab EV to EBITDA ratio is 28.48, with an EV/FCF ratio of 45.63.
- EV to Sales
- 4.12
- EV to EBITDA
- 28.48
- EV to Free Cash Flow
- 45.63
- EV to Operating Cash Flow
- 44.44
Balance Sheet
Genmab has EUR 1.50B in cash and marketable securities with EUR 5.27B in debt, giving a net cash position of -EUR 3.77B billion.
- Cash & Marketable Securities
- EUR 1.50B
- Total Debt
- EUR 5.27B
- Net Cash
- -EUR 3.77B
- Net Cash Per Share
- -EUR 6.04
- Tangible Book Value Per Share
- -EUR 5.33
Margins
Gross margin is 39.92%, with operating margin of 13.81%, and net profit margin of 8.17%.
- Gross Margin
- 39.92%
- Operating Margin
- 13.81%
- Pretax Margin
- 9.40%
- Net Profit Margin
- 8.17%
- EBITDA Margin
- 14.45%
- EBIT Margin
- 14.06%
Analyst Forecast
The average price target for Genmab is EUR 57.78, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 57.78
- Price Target Upside
- 15.56% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 11
- Revenue Growth Forecast
- 14.22%
- EPS Growth Forecast
- -40.65%
Scores
- Smart Score
- 10
- AI Score
- ―